Trial Profile

A prospective, cohort study assessing the SARS-COV-2 vaccine immunogenicity in PLWH in the Netherlands

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ad26.COV2 S (Primary) ; AZD 1222 (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
Indications COVID 2019 infections
Focus Pharmacodynamics

Most Recent Events

02 Aug 2022 Results presented at the 24th International AIDS Conference
29 Mar 2022 New trial record
16 Feb 2022 Primary endpoint (Anti-SARS-CoV-2 IgG response (Liaison Trimeric Spike IgG in BAU/ml) measured 4-6 weeks after vaccination with one of the 2 mRNA vaccines in PLWH versus controls) has been met according to the results presented at the 29th Conference on Retroviruses and Opportunistic Infections

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com